

YOU ARE INVITED

Gilead Sciences invites you to a ZYDELIG[®] (idelalisib) educational event

Zydelig: A Case Study Review

Meeting Overview

- Review key details of FDA-approved ZYDELIG Prescribing Information
- Present design of key trials, efficacy profile, and safety profile
- Learn more about dosing and dose modifications

No CME credit is offered

Presented by:

JOHN PAGEL, MD
Chief, Hematologic Malignancies Program
Swedish Cancer Institute

Date:

Saturday, August 19, 2017
12:10 PM PST

Location:

The Langham Hotel
Colonnade Meeting Room
1401 S Oak Knoll Avenue
Pasadena, CA 91106
(626) 568-3900

Please be aware that if you are a licensed US physician, any meal associated with this program is reportable under the Federal Open Payments/Sunshine Act. Gilead policy and the PhRMA Code on Interactions with Healthcare Professionals limit attendance at this promotional educational program to healthcare professionals. Accordingly, attendance by guests is not appropriate and cannot be accommodated.

Please see accompanying full Prescribing Information, including **BOXED WARNING** regarding fatal and serious toxicities of hepatotoxicity, severe diarrhea/colitis, pneumonitis, infections, and intestinal perforation.

© 2017 Gilead Sciences, Inc. All rights reserved. ZYDP0463 06/2017
Gilead, the Gilead logo, ZYDELIG, and the ZYDELIG logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies.
Other brands noted herein are the property of their respective owners.

